Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 14.5% during mid-day trading on Wednesday . The stock traded as low as C$0.28 and last traded at C$0.33. 683,132 shares traded hands during trading, an increase of 2% from the average session volume of 673,013 shares. The stock had previously closed at C$0.38.
Hemostemix Price Performance
The firm has a market capitalization of C$27.44 million, a price-to-earnings ratio of -15.75 and a beta of 0.20. The business’s fifty day simple moving average is C$0.14 and its 200 day simple moving average is C$0.10.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Using the MarketBeat Dividend Yield Calculator
- 3 Steel Stocks Soaring After Tariff Announcements
- Stock Analyst Ratings and Canadian Analyst Ratings
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- 3 Stocks to Consider Buying in October
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
